

BMI CHART

Hiranandani Fortis Hospital

Mini Seashore Road, Sector 10 - A, Vashi, Navi Mumbai - 400 703.

Tel.: +91-22-3919 9222 Fax: +91-22-3919 9220/21

Email: vashi@vashihospital.com

Signature

HEIGHT In/cm Underweight Healthy Overweight Overwe	WEIGHT Ibs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 HEIGHT In/cm Underweight Healthy Overweight Overweight 15'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 51" - 154.9 18 19 20 21 22 23 24 25 26 27 28 29 30 52" - 157.4 18 19 20 21 22 23 24 25 26 27 28 29 30 55" - 160.0 17 18 19 20 21 22 23 24 25 26 27 28 29 30 54" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 30 54" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	2 3 165 170 75.0 77.3 32 33 31 32 30 30 31 29 30	175 180 79.5 81.8 Obe 34 35 33 34	BMI:	195 2/ 88.6 90		210	s
WEIGHT Ibs	WEIGHT Ibs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 HEIGHT In/cm Underweight Healthy Overweight Overweight 5'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 5'2" - 154.9 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'3" - 160.0 17 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'4" - 162.5 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 30 5'4" - 162.5 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 26 27 28 29 30 5'5" - 170.1 15 16 17 18 19 20 20 21 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	2 3 165 170 75.0 77.3 32 33 31 32 30 30 31 29 30	175 180 79.5 81.8 Obe 34 35 33 34	BMI:	195 2/ 88.6 90		210	s
WEIGHT libs 100 105 100 115 120 125 130 135 140 145 150 155 160 165 170 175 150 185 190 195 200 205 210 211 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 75.0 77.3 79.5 81.8 84.1 86.4 86.6 90.9 93.2 95.5 97. HEIGHT in/om Underweight Healthy Overweight Overweight Obese Extremely Obese Extremely Obese	WEIGHT Ibs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 HEIGHT In/cm Underweight Healthy Overweight Overweight 15'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 51" - 154.9 18 19 20 21 22 23 24 25 26 27 28 29 30 52" - 157.4 18 19 20 21 22 23 24 25 26 27 28 29 30 55" - 160.0 17 18 19 20 21 22 23 24 25 26 27 28 29 30 54" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 30 54" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 26 27 28 29 30 55" - 165.1 16 17 18 19 20 20 21 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	2 3 165 170 75.0 77.3 32 33 31 32 30 30 31 29 30	175 180 79.5 81.8 Obe 34 35 33 34	BMI:	195 2/ 88.6 90		210	5
WEIGHT libs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 75.0 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97. HEIGHT in/cm Underweight	WEIGHT lbs kgs	165 170 75.0 77.3 32 33 31 32 30 31 29 30	175 180 79.5 81.8 Obe 34 35 33 34	185 190 84.1 86.4 se	88.6 90		210	통
WEIGHT libs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 75.0 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97. HEIGHT in/cm Underweight	WEIGHT lbs kgs 45.5 47.7 50.50 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.5 72.7 HEIGHT in/cm Underweight Healthy Overweight 5'0" - 152.4 19 20 21 22 22 23 24 25 26 27 28 29 30 31 5'1" - 154.9 18 19 20 21 22 22 23 24 25 26 27 28 29 30 31 5'2" - 157.4 18 19 20 21 22 22 23 24 24 25 26 27 28 29 30 5'3" - 160.0 17 18 19 20 21 22 22 23 24 24 25 26 27 28 29 30 5'4" - 162.5 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 30 5'4" - 162.5 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 20 21 22 23 24 24 24 25 26 27 28 25 26 27 5'6" - 167.6 16 17 17 18 19 20 20 21 22 23 24 24 24 25 25 26 27 28 25 25 25 15" - 170.1 15 16 17 18 18 19 20 20 21 22 23 24 24 25 25 25 25 25 25 15" - 170.1 15 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 25 25 15" - 170.1 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 25 25 15" - 170.2 14 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 25 15" - 170.2 14 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 15" - 170.2 14 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 15" - 170.2 14 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 15" - 170.2 14 15 16 16 17 18 18 19 20 20 21 22 22 23 24 25 25 25 25 25 25 25 25 25 25 25 25 25	165 170 75.0 77.3 32 33 31 32 30 31 29 30	175 180 79.5 81.8 Obe 34 35 33 34	185 190 84.1 86.4 se	88.6 90		210	5
kgs 45.5 47.7 50.5 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.7 77.5 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97. HEIGHT in/cm Underweight Image: Healthy Coverweight Cobese Extremely Obese 5'0" - 152.4 19 20 21 22 22 23 24 25 26 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 22 5'1" - 154.9 18 9 9 20 21 21 22 22 23 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'2" - 157.4 18 9 9 20 21 21 22 22 23 24 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'3" - 160.0 17 18 8 19 9 20 21 22 22 23 24 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'4" - 162.5 17 18 18 19 9 20 21 21 22 23 24 24 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36	HEIGHT in/cm Underweight Healthy Overweight 5'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 5'1" - 154.9 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 25 26 27 28 29 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'4" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 5'6" - 167.6 5'6" - 167.6 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'7" - 170.1 5 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'8" - 172.7 5'8" - 172.7 15 16 16 17 18 18 19 20 21 22 22 23 24 24 25 25 25 25 26 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 25 26 27 28 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 26 27 28 5'10" - 182.8 13 14 14 15 16 17 18 18 19 20 20 21 22 22 23 24 24 25 25 25 26 27 28 6'0" - 182.8 13 14 14 15 16 17 17 18 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 26 27 28 6'1" - 185.4 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	75.0 77.3 32 33 31 32 30 31 29 30	79.5 81.8 Obe 34 35 33 34	84.1 86.4 se 36 37	88.6 90		210	
kgs 45.5 47.7 50.5 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.7 77.5 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97. HEIGHT in/cm Underweight Image: Healthy Coverweight Cobese Extremely Obese 5'0" - 152.4 19 20 21 22 22 23 24 25 26 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 22 5'1" - 154.9 18 9 9 20 21 21 22 22 23 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'2" - 157.4 18 9 9 20 21 21 22 22 23 24 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'3" - 160.0 17 18 8 19 9 20 21 22 22 23 24 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'4" - 162.5 17 18 18 19 9 20 21 21 22 23 24 24 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36	HEIGHT in/cm Underweight Healthy Overweight 5'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 5'1" - 154.9 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 25 26 27 28 29 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'4" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 5'6" - 167.6 5'6" - 167.6 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'7" - 170.1 5 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'8" - 172.7 5'8" - 172.7 15 16 16 17 18 18 19 20 21 22 22 23 24 24 25 25 25 25 26 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 25 26 27 28 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 26 27 28 5'10" - 182.8 13 14 14 15 16 17 18 18 19 20 20 21 22 22 23 24 24 25 25 25 26 27 28 6'0" - 182.8 13 14 14 15 16 17 17 18 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 26 27 28 6'1" - 185.4 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	75.0 77.3 32 33 31 32 30 31 29 30	79.5 81.8 Obe 34 35 33 34	84.1 86.4 se 36 37	88.6 90		210	
kgs 45.5 47.7 50.5 52.3 54.5 56.8 59.1 61.4 63.6 65.9 68.2 70.7 77.5 77.3 79.5 81.8 84.1 86.4 88.6 90.9 93.2 95.5 97. HEIGHT in/cm Underweight Image: Healthy Coverweight Cobese Extremely Obese 5'0" - 152.4 19 20 21 22 22 23 24 25 26 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 22 5'1" - 154.9 18 9 9 20 21 21 22 22 23 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'2" - 157.4 18 9 9 20 21 21 22 22 23 24 24 25 26 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'3" - 160.0 17 18 8 19 9 20 21 22 22 23 24 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 5'4" - 162.5 17 18 18 19 9 20 21 21 22 23 24 24 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 40 5'6" - 167.6 16 17 17 18 19 9 20 21 21 22 23 24 25 25 26 27 28 29 30 31 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36 37 38 39 30 30 31 32 33 34 35 36	HEIGHT in/cm Underweight Healthy Overweight 5'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 5'1" - 154.9 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 25 26 27 28 29 5'3" - 160.0 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'4" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 29 5'5" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 29 5'6" - 167.6 5'6" - 167.6 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'7" - 170.1 5 16 17 18 18 19 20 21 22 23 24 24 25 25 26 27 28 5'8" - 172.7 5'8" - 172.7 15 16 16 17 18 18 19 20 21 22 22 23 24 24 25 25 25 25 26 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 25 26 27 28 5'10" - 177.8 14 15 16 17 17 18 19 19 20 21 22 22 23 24 24 25 25 25 25 26 27 28 5'10" - 182.8 13 14 14 15 16 17 18 18 19 20 20 21 22 22 23 24 24 25 25 25 26 27 28 6'0" - 182.8 13 14 14 15 16 17 17 18 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 26 27 28 6'1" - 185.4 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 20 21 21 22 22 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	75.0 77.3 32 33 31 32 30 31 29 30	79.5 81.8 Obe 34 35 33 34	84.1 86.4 se 36 37	88.6 90		210	
HEIGHT in/om Underweight Healthy Overweight Obese Extremely Obese Fig. 152.4 18	HEIGHT in/cm Underweight Healthy Overweight 5'0" - 152.4 19 20 21 22 23 24 25 26 27 28 29 30 31 5'1" - 154.9 18 19 20 21 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 30 5'3" - 160.0 17 18 19 20 21 22 22 23 24 25 26 27 28 29 5'4" - 162.5 17 18 18 19 20 21 22 22 23 24 24 25 26 27 28 29 5'4" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 5'6" - 165.1 16 17 18 19 20 21 22 23 24 24 25 26 27 28 5'6" - 167.6 16 17 17 18 19 20 21 22 23 24 24 25 25 26 27 28 5'6" - 170.1 15 16 17 18 19 20 20 21 22 23 24 24 25 25 26 27 5'8" - 172.7 15 16 16 17 18 18 19 20 21 22 23 24 24 25 25 25 26 5'9" - 176.2 14 15 16 17 17 18 19 20 21 22 22 23 24 25 25 25 26 5'10" - 177.8 14 15 15 16 17 17 18 19 20 20 21 22 22 23 24 24 25 25 25 26 5'10" - 182.8 13 14 14 15 16 17 18 18 19 20 20 20 21 22 22 23 24 25 25 26 27 6'3" - 185.4 6'1" - 185.4 13 13 14 15 15 16 17 17 18 18 19 20 20 21 22 22 23 24 25 25 26 27 6'3" - 190.5 12 13 14 14 15 15 16 17 17 18 19 19 20 20 21 21 22 22 23 24 25 25 26 25 26 27 28 25 26 27 28 25 26 27 28 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 22 20 23 24 25 25 26 27 28 29 20 21 22 20 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 25 25 26 27 28 29 20 21 21 22 22 23 24 24 25 25 26 27 28 29 20 21 21 22 22 23 24 24 25 25 26 27 28 29 20 21 21 22 22 23 24 24 25 25 26 27 28 29 20 21 21 22 23 24 24 25 25 26 27 28 29 20 21 21 22 22 23 24 24 24 25 25 26 27 28 29 20 21 21 22 22 23 24 24 24 25 25 26 27 28 20 20 21 21 22 22 23 24 24 24 25 25 26 27 28 20 20 21 21 22 20 23 24 24 24 25 25 26 27 28 20 20 21 21 22 20 23 24 24 24 25 25 26 27 28 20 20 21 21 22 20 23 24 24 24 25 25 26 27 28 20 20 21 21 22 20 20 20 21	32 33 31 32 30 31 29 30	Obe 34 35 33 34	se 36 37	Name of the last			215
50" - 152.4 18	5'0" - 152.4	32 33 33 31 32 30 31 29 30 30	34 35 33 34	36 37				
51" - 154.9	5'1" - 154.9 18 19 20 21 22 23 24 25 26 27 28 29 30 5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 5'3" - 160.0 17 18 19 20 21 22 23 24 24 25 26 27 28 29 5'4" - 162.5 17 18 19 20 21 22 23 24 24 25 26 27 28 5'5" - 165.1 16 17 18 19 20 21 22 23 24 25 25 26 27 5'6" - 167.6 16 17 17 18 19 20 21 21 22 23 24 25 <td>31 32 30 31 29 30</td> <td>33 34</td> <td></td> <td></td> <td></td> <td></td> <td></td>	31 32 30 31 29 30	33 34					
5'2" - 157.4	5'2" - 157.4 18 19 20 21 22 22 23 24 25 26 27 28 29 5'3" - 160.0 17 18 19 20 21 22 23 24 24 25 26 27 28 5'4" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 28 5'5" - 165.1 16 17 18 19 20 21 22 23 24 25 26 27 5'6" - 167.6 16 17 18 19 20 21 21 22 23 24 25 25 26 5'7" - 170.1 15 16 17 18 19 20 21 22 23 24 25 25 25 5'8" - 172.7 15 16 17 18 19 19 20 21 22 23 24 25 5'9" - 176.2 14 15 16	30 31 29 30					1000	42
5'3" - 160.0	5'3" - 160.0 17 18 19 20 21 22 23 24 24 25 26 27 28 5'4" - 162.5 17 18 18 19 20 21 22 23 24 24 25 26 27 5'5" - 165.1 16 17 18 19 20 21 22 23 24 25 25 26 5'6" - 167.6 16 17 18 19 20 21 21 22 23 24 25 25 26 5'7" - 170.1 15 16 17 18 18 19 20 21 22 22 23 24 25 25 5'8" - 172.7 15 16 16 17 18 19 19 20 21 22 22 23 24 25 5'9" - 176.2 14 15 16 17 17 18 19 20 20 21 22 23 24 25 25 25	29 30	32 33					
5'4" - 162.5	5'4" - 162.5		24 20			and America		-
5'5" - 165.1	5'5" - 165.1	20 111-20	-			CIO MANAGEMENT		edit of the
5'6" - 167.6	5'6" - 167.6	100						dente es
5'7" - 170.1	5'7" - 170.1					NAME OF TAXABLE PARTY.		2 150
5'8" - 172.7	5'8" - 172.7				PRINCE IN			
5'9" - 176.2	5'9" - 176.2 14 15 16 17 18 19 20 20 21 22 22 23 5'10" - 177.8 14 15 15 16 17 18 18 19 20 20 21 22 23 23 5'11" - 180.3 14 14 15 16 16 17 18 18 19 20 21 21 22 23 6'0" - 182.8 13 14 14 15 16 17 17 18 19 19 20 21 21 22 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 21 21 6'2" - 187.9 12 13 14 14 15 16 16 17 18 18 19 19 20 21 21 6'3" - 190.5 12 13 13 14 15 15 16 16 17 18 18 19					-	_	32
5'10" - 177.8	5'10" - 177.8 14 15 15 16 17 18 18 19 20 20 21 22 23 5'11" - 180.3 14 14 15 16 16 17 18 18 19 20 21 21 21 22 25 6'0" - 182.8 13 14 14 15 16 17 17 18 19 19 20 21 21 21 21 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 21 21 21 6'2" - 187.9 12 13 14 14 15 16 16 17 18 18 19 19 20 21 20 21 20 21 20 21 20 21 20 21 21 20 21 20 21 20 21 20 21 20 21 20 21 20 21 20 21 20 <	24 25	25 26	27 28	28 29	9 30	31	31
5'11" - 180.3	5'11" - 180.3 14 14 15 16 16 17 18 18 19 20 21 21 22 6'0" - 182.8 13 14 14 15 16 17 17 18 19 19 20 21 21 21 6'1" - 185.4 13 13 14 15 15 16 17 17 18 19 19 20 21 21 6'2" - 187.9 12 13 14 14 15 16 16 17 18 18 19 19 20 21 6'3" - 190.5 12 13 13 14 15 15 16 16 17 18 18 19 20 6'4" - 193.0 12 13 14 14 15 15 16 16 17 18 18 19 20	23 24	25 25	26 27	28 28	29	30	30
6'1" - 185.4 13	6'1" - 185.4 6'2" - 187.9 12 13 14 15 15 16 17 17 18 19 19 20 21 6'3" - 190.5 6'4" - 193.0 13 14 15 15 16 16 17 18 18 19 19 20 21 21 20 20 21 20 21 20 21 20 21 20 21 20 21 20 20 21 20 21 20 20 21 20 21 20 20 21 20 20 21 20 20 21 20 20 21 20 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	23 23	24 25	25 26	27 28	28	29	30
6'2" - 187.9	6'2" - 187.9	22 23	23 24	25 25	26 2	7 27	28	29
6'3" - 190.5	6'3" - 190.5	21 22	23 23	24 25	25 26	6 27	27	28
6'4" - 193.0 12 12 13 14 14 15 15 16 17 17 18 18 19 20 20 21 22 22 23 23 24 25 25 26	6'4" - 193.0 12 12 13 14 14 15 15 16 17 17 18 18 19						27	27
04 - 193.0	04 - 193.0	-	-				26	26
Doctors Notes:	Doctors Notes:	20 20	21 22	22 23	23 2	25	25	26
Doctors Notes:	Doctors Notes:							
Doctors Notes:	Doctors Notes:							

								¥.
	er .							
9	8 0							
*								
*	*							
			:					

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255 For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



(A 12 Fortis Network Hospital)

Date:25/03/23 Sex/age: F/37 Health Check-up

UHID: 12372995

Name: Mrs. Jillela Sravanthi

OPD:PAP

Drug allergy: Sys illness:

P212 - Both LSCE.
Bohn 57 71045 The done.

Adu.
Felv extrer

000

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300 www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D



(A 12 Fortis Network Hospital)

Date:25/03/23 Sex/age: F/37 Health Check-up

Drug allergy: -> Not kunsys illness: -> No

UHID: 12372995

Name:Mrs.Jillela Sravanthi

OPD: Opthal 14

Hiranandani Healthcare Pvt. Ltd. Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D

UHID: 12372995

Name:Mrs.Jillela Sravanthi

OPD: Dental 12



7387696540—

Date:25/03/23 Sex/age: F/37 Health Check-up

MLH

Drug allergy: U/A
Sys illness:

0/8

Stairs +

1995al Carres c

Dalusal Carries

upper producation

Treatment plan

Adv 1 -

6 Scaling

- filling c 87

- JOPA E 4

~ Offhodoutic Treatment

4

8.7 78

8778

pr. Terry





PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO: 0022WC004890

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female

:25/03/2023 09:43:00 DRAWN RECEIVED: 25/03/2023 09:43:17

REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval Units

HA	EMATOLOGY - CBC		
CBC-5, EDTA WHOLE BLOOD			.(4.2)4.2)4(4)4.4.4.4.4.(8)2.4.(
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: SPECTROPHOTOMETRY	12.2	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.70	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DHSS)CT	6.61 YTOMETRY	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRICAL IMPEDANCE	332	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	36.0	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	76.6 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	25.9 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.9	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.6	11.6 - 14.0	%
MENTZER INDEX	16.3		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	8.7	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: FLOWCYTOMETRY	51	40 - 80	%
LYMPHOCYTES METHOD: FLOWCYTOMETRY	39	20 - 40	%

Dr.Akta Dubev **Counsultant Pathologist**



Page 1 Of 14



Email: -

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WC004890

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female :25/03/2023 09:43:00 DRAWN

RECEIVED: 25/03/2023 09:43:17 REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

BILLNO-1501230PCR017321		_ 9 _ 9 _ 59 _ 595_ 59	22 4 22 42
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
MONOCYTES METHOD: FLOWCYTOMETRY	7	2 - 10	%
EOSINOPHILS METHOD: FLOWCYTOMETRY	3	1 - 6	%
BASOPHILS METHOD: FLOWCYTOMETRY	0	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	3.37	2.0 - 7.0	thou/μL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.58	1.0 - 3.0	thou/μL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.46	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.20	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD: CALCULATED PARAMETER	1.3		
MORPHOLOGY			
RBC METHOD: MICROSCOPIC EXAMINATION	PREDOMINANTLY	NORMOCYTIC NORMOCHROMIC	, MILD MICROCYTOSIS
WBC	NORMAL MORPHO	LOGY	
METHOD : MICROSCOPIC EXAMINATION			
LATELETS METHOD: MICROSCOPIC EXAMINATION	ADEQUATE		

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

Dr.Akta Dubey **Counsultant Pathologist**





Page 2 Of 14



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Fmail: -





REF. DOCTOR: SELF



PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

ACCESSION NO : 0022WC004890

Female AGE/SEX :37 Years

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

:25/03/2023 09:43:00 DRAWN RECEIVED: 25/03/2023 09:43:17

MUMBAI 440001

ARHA NO

REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status Final

Results

Biological Reference Interval Units

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Akta Dubey **Counsultant Pathologist**

Page 3 Of 14

PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







Female

PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO: 0022WC004890

: FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

PATTENT ID

AGE/SEX :37 Years

:25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17 REPORTED: 25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval

DRAWN

Units

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R

10

0 - 20

mm at 1 hr

METHOD: WESTERGREN METHOD

Interpretation(s)

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:
Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue Injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akta Dubey **Counsultant Pathologist**

Page 4 Of 14

PERFORMED AT :

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO: 0022WC004890

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years DRAWN

Female :25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17

REPORTED: 25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval

Units

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

RH TYPE

TYPE O

METHOD: TUBE AGGLUTINATION

POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Page 5 Of 14

Dr. Akta Dubey Counsultant Pathologist



PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Fmail : -







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO: 0022WC004890

PATIENT ID : FH.12372995

CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female DRAWN :25/03/2023 09:43:00

RECEIVED :25/03/2023 09:43:17 REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status Final Results

Biological Reference Interval Units

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.48	0.2 - 1.0	mg/dL
METHOD : JENDRASSIK AND GROFF			
BILIRUBIN, DIRECT METHOD: JENDRASSIK AND GROFF	0.14	0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.34	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET	7.3	6.4 - 8.2	g/dL
ALBUMIN METHOD: BCP DYE BINDING	3.8	3.4 - 5.0	g/dL
GLOBULIN METHOD: CALCULATED PARAMETER	3.5	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.1	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV WITH PSP	14 Low	15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV WITH P5P	15	< 34.0	U/L
ALKALINE PHOSPHATASE METHOD: PNPP-ANP	63	30 - 120	U/L
JAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	21	5 - 55	U/L
LACTATE DEHYDROGENASE METHOD: LACTATE - PYRUVATE	103	100 - 190	U/L
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: HEXOKINASE	96	74 - 99	mg/dL

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

Do. A

Dr.Akta Dubey Counsultant Pathologist

Page 6 Of 14

View Detail

View Repor



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956 Email: -







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO : 0022WC004890 PATIENT ID : FH.12372995

CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female :25/03/2023 09:43:00 DRAWN

RECEIVED: 25/03/2023 09:43:17

REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
HBA1C	5.8 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)	%
METHOD: HB VARIANT (HPLC)			***
ESTIMATED AVERAGE GLUCOSE(EAG) METHOD: CALCULATED PARAMETER	119.8 High	< 116.0	mg/dL
KIDNEY PANEL - 1			
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	10	6 - 20	mg/dL
METHOD: UREASE - UV			
CREATININE EGFR- EPI	0.71	0.60 - 1.10	mg/dL
CREATININE METHOD: ALKALINE PICRATE KINETIC JAFFES	0.71	0.00 - 1.10	mg/dc
AGE	37		years
GLOMERULAR FILTRATION RATE (FEMALE) METHOD: CALCULATED PARAMETER	112.24	Refer Interpretation Below	mL/min/1.73m2
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	14.08	5.00 - 15.00	
URIC ACID, SERUM			
URIC ACID	2.9	2.6 - 6.0	mg/dL
METHOD: URICASE UV			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: BIURET	7.3	6.4 - 8.2	g/dL
ALBUMIN, SERUM			
ALBUMIN	3.8	3.4 - 5.0	g/dL
METHOD : BCP DYE BINDING			
GLOBULIN			

Dr.Akta Dubey Counsultant Pathologist Page 7 Of 14





PERFORMED AT :

Email: -

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAT 440001

REF. DOCTOR: SELF

ACCESSION NO: 0022WC004890

: FH.12372995

CLIENT PATIENT ID: UID:12372995

ABHA NO

PATIENT ID

AGE/SEX :37 Years Female :25/03/2023 09:43:00 DRAWN

RECEIVED: 25/03/2023 09:43:17 REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 DTILNO 1E01220000017221

BILLINO-1501250PCR017521			
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
GLOBULIN METHOD: CALCULATED PARAMETER	3,5	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM		200 170	F/I
SODIUM, SERUM METHOD: ISE INDIRECT	137	136 - 145	mmol/L
POTASSIUM, SERUM METHOD: ISE INDIRECT	4.49	3.50 - 5.10	mmol/L
CHLORIDE, SERUM METHOD: ISE INDIRECT	103	98 - 107	mmol/L
Interpretation(s)			

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg., hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg.,
obstruction and hepatitis), and abnormal bilirubin metabolism (eg., hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated
(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when
there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin
may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that
attaches sugar molecules to bilirubin.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection,ischemia to the liver,chronic epatitis, obstruction of bile ducts, cirrhosis.

In its approximation of bile ducts, cirrhosis.

epatitis, obstruction of bile ducts, cirrhosis.

LP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget "s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson "s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme—inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom***

Syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypopalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, etc. Plasma. Test DESCRIPTION

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Page 8 Of 14

Dr.Akta Dubey Counsultant Pathologist





PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel : 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO: 0022WC004890

: FH.12372995 PATTENT ID CLIENT PATIENT ID: UID:12372995

ABHA NO

:37 Years Female AGE/SEX :25/03/2023 09:43:00 DRAWN

RECEIVED: 25/03/2023 09:43:17 REPORTED: 25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval

Units

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in Pancreatic Islet cell disease with increased insulin insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1.Evaluating the long-term control of blood glocose cutred as 2.Diagnosing diabetes.
2.Diagnosing diabetes.
3.Identifying patients at increased risk for diabetes (prediabetes).
3.Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range, well-controlled type 2 diabetic patients, and 2 times per year for the ADA recommends well-controlled type 2 diabetic patients, and 2 times per year for the ADA recommends within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to:

I. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower that Late test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

III. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Interference of hemoglobinopathy is reported to increase test results. Hypertriglyceridentia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV. Interference of hemoglobinopathies in HbA1c estimation is seen in a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c. HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

BLOOD UREA NTROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Budyaration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is excreted and concentrations increase in the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined.

A GFR of 60 or higher is in the normal range.

\ GFR of 60 or higher is in the normal range.

\ GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney function than serum creatinine alone.

Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated than the CKD-EPI creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation, especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Syndrome
Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis
TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom

Dr.Akta Dubey

Counsultant Pathologist



Page 9 Of 14

PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956









PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO: 0022WC004890

PATTENT ID : FH.12372995

CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female :25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17

REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval Units

DRAWN

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Akta Dubey **Counsultant Pathologist**



Page 10 Of 14

PERFORMED AT :

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956

Fmail: -







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO : 0022WC004890

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years DRAWN

Female :25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17

REPORTED: 25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status Final

Biological Reference Interval

BIOCHEMISTRY - LIPID

Results

TPTD	PRO	FTIF	SERL	IM

CHOLESTEROL, TOTAL

149

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: ENZYMATIC/COLORIMETRIC, CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

TRIGLYCERIDES

65

< 150 Normal

mg/dL

150 - 199 Borderline High 200 - 499 High

>/=500 Very High

METHOD : ENZYMATIC ASSAY

METHOD : DIRECT MEASURE - PEG

LDL CHOLESTEROL, DIRECT

HDL CHOLESTEROL

52

88

< 40 Low >/=60 High mg/dL

< 100 Optimal

mg/dL

100 - 129 Near or above optimal 130 - 159 Borderline High

160 - 189 High

>/= 190 Very High

METHOD: DIRECT MEASURE WITHOUT SAMPLE PRETREATMENT

NON HDL CHOLESTEROL

97

Desirable: Less than 130 Above Desirable: 130 - 159

Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

METHOD: CALCULATED PARAMETER

/FRY LOW DENSITY LIPOPROTEIN

13.0

METHOD: CALCULATED PARAMETER

</= 30.0

mg/dL

mg/dL

CHOL/HDL RATIO

2.9 Low

3.3 - 4.4 Low Risk

4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk

> 11.0 High Risk

METHOD: CALCULATED PARAMETER

LDL/HDL RATIO

1.7

0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Dr.Akta Dubev

Counsultant Pathologist





Page 11 Of 14

PERFORMED AT :

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

Final

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO: 0022WC004890

: FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

PATIENT ID

AGE/SEX : 37 Years Female :25/03/2023 09:43:00 DRAWN

RECEIVED: 25/03/2023 09:43:17 REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Results

Biological Reference Interval Units

Interpretation(s)

Dr.Akta Dubey **Counsultant Pathologist**

Page 12 Of 14

PERFORMED AT :

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR : SELF

ACCESSION NO : 0022WC004890

: FH.12372995

CLIENT PATIENT ID: UID: 12372995

ABHA NO

PATIENT ID

AGE/SEX :37 Years

DRAWN

:25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17

REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016

CORP-OPD

BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval

Units

CLINICAL PATH - URINALYSIS

KIDNEY PANEL - 1

PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD: PHYSICAL **APPEARANCE**

SLIGHTLY HAZY

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

6.5

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

PROTEIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

DETECTED (TRACE)

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN

BII TRUBIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

'JROBILINOGEN

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NOT DETECTED

NOT DETECTED

NITRITE METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

0 - 1

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

Dr. Rekha Nair, MD

Page 13 Of 14

Dr. Akta Dubey **Counsultant Pathologist**

Microbiologist



PERFORMED AT:

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,

CIN - U74899PB1995PLC045956 Email: -











PATIENT NAME: MRS.JILLELA SRAVANTHI REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO: 0022WC004890

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female DRAWN :25/03/2023 09:43:00

RECEIVED :25/03/2023 09:43:17 REPORTED :25/03/2023 12:53:40

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321

BILL NO-1501230PCR017321

BILLNO-1301230PCR017321					
Test Report Status <u>Final</u>	Results	Biological Referenc	Biological Reference Interval Units		
PUS CELL (WBC'S) METHOD: MICROSCOPIC EXAMINATION	2-3	0-5	/HPF		
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	5-7	0-5	/HPF		
CASTS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED				
CRYSTALS METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED				
BACTERIA METHOD: MICROSCOPIC EXAMINATION	DETECTED	NOT DETECTED			
YEAST METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED			
REMARKS	URINARY MICROSCOF CENTRIFUGED SEDIM	PIC EXAMINATION DONE ON ENT	URINARY		

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Dient

Interpretation(s)

Dr.Akta Dubey Counsultant Pathologist Ruche. N

Dr. Rekha Nair, MD Microbiologist Page 14 Of 14





View Details

View Report



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

REF. DOCTOR :

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD

FORTIS HOSPITAL # VASHI,

MUMBAI 440001

ACCESSION NO: 0022WC004981

PATIENT ID : FH.12372995 CLIENT PATIENT ID: UID:12372995

ABHA NO

AGE/SEX :37 Years Female

:25/03/2023 12:50:00 DRAWN

RECEIVED : 25/03/2023 12:50:41

REPORTED :25/03/2023 14:25:03

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval

Units

BIOCHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

93

70 - 139

mg/dL

METHOD : HEXOKINASE

Comments

NOTE: - POST PRANDIAL PLASMA GLUCOSE VALUES. TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin response & sensitivity etc. Additional test HbA1c treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc. Additional test HbA1c **End Of Report**

Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey Counsultant Pathologist



Page 1 Of 1



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322, CIN - U74899PB1995PLC045956







PATIENT NAME: MRS.JILLELA SRAVANTHI

CODE/NAME & ADDRESS : C000045507 - FORTIS

FORTIS VASHI-CHC -SPLZD FORTIS HOSPITAL # VASHI,

MUMBAI 440001

REF. DOCTOR: SELF

ACCESSION NO : 0022WC004890

: FH.12372995

CLIENT PATIENT ID: UID:12372995

ABHA NO

PATIENT ID

:37 Years AGE/SEX

DRAWN

Female :25/03/2023 09:43:00

RECEIVED: 25/03/2023 09:43:17 REPORTED: 25/03/2023 16:33:29

CLINICAL INFORMATION:

UID:12372995 REQNO-1431016 CORP-OPD BILLNO-1501230PCR017321 BILLNO-1501230PCR017321

Test Report Status

Final

Results

Biological Reference Interval Units

ng/dL

µg/dL

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

152.60

Non-Pregnant Women

80.0 - 200.0

Pregnant Women

1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0

3rd Trimester: 135.0 - 262.0

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

T4

8.91

Non-Pregnant Women

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

TSH (ULTRASENSITIVE)

2.240

0.270 - 4.200

µIU/mL

Interpretation(s)

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam **Consultant Pathologist**

Page 1 Of 1

PERFORMED AT:

SRL Ltd BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,

CIN - U74899PB1995PLC045956



Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF NIC UHID | Episode No : 12372995 | 17508/23/1501

Date: 27/Mar/2023

Name: Mrs. Jillela Sravanthi

Age | Sex: 37 YEAR(S) | Female

Order Station: FO-OPD **Bed Name:**

Order No | Order Date: 1501/PN/OP/2303/36501 | 25-Mar-2023 Admitted On | Reporting Date: 27-Mar-2023 14:26:03

Order Doctor Name : Dr.SELF .

ECHOCARDIOGRAPHY TRANSTHORACIC

FINDINGS:

- No left ventricle regional wall motion abnormality at rest.
- Normal left ventricle systolic function. LVEF = 60%.
- No left ventricle diastolic dysfunction.
- No left ventricle Hypertrophy. No left ventricle dilatation.
- Structurally normal valves.
- No mitral regurgitation.
- No aortic regurgitation. No aortic stenosis.
- No tricuspid regurgitation. No pulmonary hypertension.
- Intact IAS and IVS.
- No left ventricle clot/vegetation/pericardial effusion.
- Normal right atrium and right ventricle dimensions.
- Normal left atrium and left ventricle dimension.
- Normal right ventricle systolic function. No hepatic congestion.

M-MODE MEASUREMENTS:

		Two en order
A	34	mm
	23	mm
AO Root	21	mm
AO CUSP SEP	24	mm
LVID (s)		mm
LVID (d)	40	
IVS (d)	09	mm
	10	mm
LVPW (d)	27	mm
RVID (d)	30	mm
RA	60	%
LVEF		- نسا

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF NIC

Date: 27/Mar/2023

Name: Mrs. Jillela Sravanthi Age | Sex: 37 YEAR(S) | Female

Order Station : FO-OPD

Bed Name:

UHID | Episode No : 12372995 | 17508/23/1501

Order No | Order Date: 1501/PN/OP/2303/36501 | 25-Mar-2023 Admitted On | Reporting Date : 27-Mar-2023 14:26:03

Order Doctor Name: Dr.SELF.

DOPPLER STUDY:

E WAVE VELOCITY: 0.9 m/sec. A WAVE VELOCITY: 0.6 m/sec

E/A RATIO:1.5

	PEAK (mmHg)	MEAN (mmHg)	V max (m/sec)	GRADE OF REGURGITATION
	N N			Nil
MITRAL VALVE	IN O.F			Nil
AORTIC VALVE	05			Nil
TRICUSPID VALVE	N			Nil
PULMONARY VALVE	2.0			INII

Final Impression:

Normal 2 Dimensional and colour doppler echocardiography study.

DR. PRASHANT PAWAR DNB(MED), DNB (CARDIOLOGY)

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

Name: Mrs. Jillela Sravanthi

Order Station: FO-OPD

Age | Sex: 37 YEAR(S) | Female

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D





DEPARTMENT OF RADIOLOGY

UHID | Episode No : 12372995 | 17508/23/1501

Date: 25/Mar/2023

Order No | Order Date: 1501/PN/OP/2303/36501 | 25-Mar-2023

Admitted On | Reporting Date : 25-Mar-2023 13:00:06

Order Doctor Name: Dr.SELF.

X-RAY-CHEST- PA

Findings:

Bed Name:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appear normal.

Both costophrenic angles are well maintained.

Bony thorax appears unremarkable.

DR. ADITYA NALAWADE

M.D. (Radiologist)

0 E 02 2022

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D



Date: 25/Mar/2023

DEPARTMENT OF RADIOLOGY

Name: Mrs. Jillela Sravanthi

Ara | Sov. 37 VEAR(S) | Female

Order No | Order Date: 1501/PN/OP/2303/36501 | 25-Mar-2023

Age | Sex: 37 YEAR(S) | Female
Order No | Order Date: 1501/FNOF/2305/30301 | 25-Mar-2020
Admitted On | Reporting Date: 25-Mar-2023 11:47:50

Bed Name: Order Doctor Name: Dr.SELF.

US-WHOLE ABDOMEN

LIVER is normal in size and echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

GALL BLADDER is physiologically distended. Gall bladder reveals normal wall thickness. No evidence of calculi in gall bladder. No evidence of pericholecystic collection. **CBD** appears normal in caliber.

SPLEEN is normal in size and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 10.3 x 3.7 cm. Left kidney measures 10.3 x 4.2 cm.

PANCREAS is normal in size and morphology. No evidence of peripancreatic collection.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

UTERUS is normal in size, measuring 8.8 x 5.7 x 6.1 cm. A subserosal fibroid of size 4.7 x 3.7 x 3.9 cm is seen at right posterolateral wall.

Endometrium measures 8.5 mm in thickness.

Both ovaries are normal. Right ovary measures 2.4 x 1.9 x 2.6 cm, volume 6.7 cc. Left ovary measures 3.1 x 1.9 x 3.0 cm, volume 9.8 cc.

No evidence of ascites.

Impression:

· Uterine fibroid as described.

DR. CHETAN KHADKE

M.D. (Radiologist)

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN: 27AABCH5894D1ZG PAN NO: AABCH5894D

(For Billing/Reports & Discharge Summary only)





DEPARTMENT OF RADIOLOGY

Date: 27/Mar/2023

Name: Mrs. Jillela Sravanthi

Age | Sex: 37 YEAR(S) | Female

Order Station: FO-OPD

Bed Name:

UHID | Episode No: 12372995 | 17508/23/1501

Order No | Order Date: 1501/PN/OP/2303/36501 | 25-Mar-2023

Admitted On | Reporting Date : 27-Mar-2023 09:45:11

Order Doctor Name: Dr.SELF.

MAMMOGRAM - BOTH BREAST

Findings:

Bilateral film screen mammography was performed in cranio-caudal and medio-lateral oblique

Both breasts show scattered areas of fibroglandular density.

No evidence of any dominant mass, clusters of microcalcifications, nipple retraction, skin thickening or abnormal vascularity is seen in either breast.

No evidence of axillary lymphadenopathy.

IMPRESSION:

- No significant abnormality detected. (BI-RADS category I).
- · No obvious mass lesion in the breasts.

Normal-interval follow-up is recommended.

DR. YOGINI SHAH

DMRD., DNB. (Radiologist)